ProQR Therapeutics N.V. (PRQR) Fair Value 2026

PRQR · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.0 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (32/100)

Quick Summary — As of 2026-08-28, ProQR Therapeutics N.V. (PRQR) trades at $2.29. QOC: 6.0/10. Value Trap Risk: 32/100 (LOW). 0/13 models active.

Key Facts

Ticker
PRQR
Price
$2.29
Quality Score
6.0/10
Value Trap Risk
32/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give PRQR?

0 Intrinsic Value Models vs. Current Price ($2.29)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is ProQR Therapeutics N.V. (PRQR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, ProQR Therapeutics N.V. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About PRQR?

0 of 13 models are currently active for PRQR. See which stocks rank higher →

How Does PRQR Rank in Biotechnology?

Among 625 Biotechnology stocks, PRQR ranks #144 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, ProQR Therapeutics N.V. operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating PRQR should weigh these sector-specific dynamics alongside our model-derived fair values.

Is PRQR a Value Trap?

CirclFi's Value Trap algorithm assigns PRQR a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for ProQR Therapeutics N.V.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, ProQR Therapeutics N.V.'s fundamental quality profile registers 6.0/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PRQR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy ProQR Therapeutics N.V. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

VALNValneva SEQOC 6.0ALECAlector, Inc.QOC 6.0LPCNLipocine Inc.QOC 6.1KURAKura Oncology, Inc.QOC 6.0INMBINmune Bio Inc.QOC 6.1CAICaris Life Sciences, Inc.QOC 6.0FULCFulcrum Therapeutics, Inc.QOC 5.1LIMNLiminatus Pharma, Inc.QOC 4.5MESOMesoblast LimitedQOC 2.3EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: VALN · ALEC · LPCN · KURA · INMB · CAI · FULC · LIMN · MESO · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to PRQR?

7 companies across all industries closest to PRQR’s Quality of Company score of 6.0/10.

PBHCPathfinder Bancorp, Inc.QOC 6.0MPTMedical Properties Trust, Inc.QOC 6.0KRUSKura Sushi USA, Inc.QOC 6.0FUBOFuboTV Inc.QOC 6.0KLNGKoil Energy Solutions, Inc.QOC 6.0CURRCURRENC Group Inc.QOC 6.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: PBHC · MPT · KRUS · FUBO · KLNG · CURR · NVDA

Where Does PRQR Sit in CirclFi's Biotechnology Rankings?

PRQR is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About ProQR Therapeutics N.V.’s Valuation?

What is ProQR Therapeutics N.V.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for ProQR Therapeutics N.V. (PRQR). The Quality of Company score is 6.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PRQR overvalued or undervalued right now?

At $2.29, 0 of 0 active models suggest PRQR may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits ProQR Therapeutics N.V.'s business model in Biotechnology.

What does a Quality of Company score of 6.0 mean for PRQR?

ProQR Therapeutics N.V.'s QOC of 6.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on PRQR?

CirclFi analyzes PRQR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is PRQR a value trap in 2026?

ProQR Therapeutics N.V.'s Value Trap score is 32/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns ProQR Therapeutics N.V. (PRQR) a Quality of Company score of 6.0/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/PRQR/ · Methodology
Primary sources for this PRQR valuation
  • Financial statements: ProQR Therapeutics N.V. 10-K and 10-Q filings on SEC EDGAR (CIK 0001612940) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PRQR as of ; valuations recomputed .